Merck KGaA to Acquire Silence Therapeutics in All-Cash Deal
Silence Therapeutics said it agreed to be purchased by Germany's Merck KGaA in an all-cash deal for its gene-silencing technology. The headline states Merck is paying a 130% premium.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Merck KGaA to acquire Silence Therapeutics for about $1.3 billion
Merck KGaA said it will acquire Silence Therapeutics in an all-cash deal valued at about $1.3 billion.